Inhibikase Therapeutics, Inc.
IKT· Nasdaq
IKTInhibikase Therapeutics, Inc.
Quarterly figures for Inhibikase Therapeutics, Inc., with source filings when available.
26 quarters. Mar 31, 2020 to Jun 30, 2026. USD.
Inhibikase Therapeutics, Inc. has filed its 10-Q within 42 to 45 days of period end across its last 8 quarters. The 10-K runs 85 to 90 days.
Inhibikase Therapeutics, Inc. · CIK 1750149 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | |||||||||
| Q2 2026 | Jun 30, 2026 | Aug 11, 2026 · after-hours | Aug 11, 2026 | 42 d | 10-Q | $0.00 | — | -$0.11 | |
| Q1 2026 |
|---|
| Mar 31, 2026 |
| May 12, 2026 · after-hours |
| May 12, 2026 |
| 42 d |
| 10-Q |
| $0.00 |
| — |
| -$0.10 |
| FY 2025 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2025derived | Dec 31, 2025 | Mar 26, 2026 · after-hours | Mar 26, 2026 | 85 d | 10-K | — | — | — | |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 · after-hours | Nov 14, 2025 | 45 d | 10-Q | $0.00 | — | -$0.13 | |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 · after-hours | Aug 14, 2025 | 45 d | 10-Q | $0.00 | — | -$0.11 | |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 · after-hours | May 14, 2025 | 44 d | 10-Q | $0.00 | — | -$0.15 | |
| FY 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | Mar 27, 2025 · after-hours | Mar 27, 2025 | 86 d | 10-K | $0.00 | −100.0% | — | |
| Q3 2024 | Sep 30, 2024 | — | Nov 14, 2024 | 45 d | 10-Q | $0.00 | −100.0% | -$0.65 | |
| Q2 2024 | Jun 30, 2024 | — | Aug 14, 2024 | 45 d | 10-Q | $0.00 | −100.0% | -$0.66 | |
| Q1 2024 | Mar 31, 2024 | — | May 15, 2024 | 45 d | 10-Q | $0.00 | −100.0% | -$0.73 | |
| FY 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | — | Mar 27, 2024 | 87 d | 10-K | $1.00 | −100.0% | — | |
| Q3 2023 | Sep 30, 2023 | — | Nov 14, 2023 | 45 d | 10-Q | $79.57K | +991.3% | -$0.86 | |
| Q2 2023 | Jun 30, 2023 | — | Aug 14, 2023 | 45 d | 10-Q | $116.41K | +1,676.7% | -$1.11 | |
| Q1 2023 | Mar 31, 2023 | — | May 15, 2023 | 45 d | 10-Q | $64.52K | +40.2% | -$0.98 | |
| FY 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2022derived | Dec 31, 2022 | — | Mar 31, 2023 | 90 d | 10-K | $63.57K | +3,169.9% | — | |
| Q3 2022 | Sep 30, 2022 | — | Nov 14, 2022 | 45 d | 10-Q | $7.29K | −97.8% | -$1.06 | |
| Q2 2022 | Jun 30, 2022 | — | Aug 12, 2022 | 43 d | 10-Q | $6.55K | −99.5% | -$1.10 | |
| Q1 2022 | Mar 31, 2022 | — | May 16, 2022 | 46 d | 10-Q | $46.03K | −96.7% | -$0.18 | |
| FY 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2021derived | Dec 31, 2021 | — | Mar 31, 2022 | 90 d | 10-K | $1.94K | −98.9% | — | |
| Q3 2021 | Sep 30, 2021 | — | Nov 15, 2021 | 46 d | 10-Q | $328.46K | +771.7% | -$0.18 | |
| Q2 2021 | Jun 30, 2021 | — | Aug 16, 2021 | 47 d | 10-Q | $1.36M | +520.7% | -$0.22 | |
| Q1 2021 | Mar 31, 2021 | Apr 1, 2021 · market hours | May 17, 2021 | 47 d | 10-Q | $1.41M | +419.7% | -$0.26 | |
| FY 2020 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2020derived | Dec 31, 2020 | — | Mar 31, 2021 | 90 d | 10-K | $170.42K | — | — | |
| Q3 2020 | Sep 30, 2020 | — | — | — | — | $37.68K | — | -$0.08 | |
| Q2 2020 | Jun 30, 2020 | — | — | — | — | $219.59K | — | -$0.05 | |
| Q1 2020 | Mar 31, 2020 | — | — | — | — | $270.79K | — | -$0.07 | |
